Variable Expression of Notch1 and Pax5 in Classical Hodgkin Lymphoma and Infection with Epstein–Barr in Pediatric Patients

• Main Authors: Icela Palma-Lara, Ana Elena Sánchez-Aldana, Elva Jiménez-Hernández, Octavio Martínez-Villegas, Juan Carlos Núñez-Enríquez, Juan Manuel Mejía-Aranguré, Sara A. Ochoa, Juan Xicohtencatl-Cortes, Ariadnna Cruz-Córdova, Sergio Zavala-Vega, Mariana García-Jiménez, Alejandra Contreras-Ramos, José Refugio Torres-Nava, Guillermo Mora-Ramiro, José Arellano-Galindo
• Format: Article
• Language: English
• Published: MDPI AG 2020-06-01
• Series: Microorganisms
• Subjects: Epstein–Barr virus 1; Hodgkin lymphoma; NOTCH1; PAX5
• Online Access: https://www.mdpi.com/2076-2607/8/6/958

NOTCH1 and PAX5 participate in the proliferation and differentiation of B and T lymphocytes. Their expression can be modified by activation of NOTCH1, induced by the Epstein–Barr (EBV) viral proteins identified as LMP1 and LMP2. To identify whether PAX5, NOTCH1, and EBV latency genes participate in the oncogenic process of pediatric patients with classical Hodgkin lymphoma (cHL), the present study aimed to identify the variable expression of NOTCH1 among disease subtypes and to assess its effect on PAX5 expression. A total of 41 paraffin-embedded tissues from Mexican pediatric patients with cHL were analyzed. The expression of CD30, CD20, NOTCH1, PAX5, and LMP1 was evaluated by immunohistochemistry and immunofluorescence. EBV detection was performed by in situ hybridization. Out of all cases, 78% (32/41) of the cHL cases were EBV positive. NOTCH1 expression was detected in 78.1% (25/32) of EBV-positive cases, nodular sclerosis being the most frequent subtype (11/25, 44%). In cases where the expression of both genes was identified, double immunofluorescence assays were conducted, finding no colocalization. We found that Reed–Sternberg cells had aberrant expression compared to their cells of origin (B lymphocytes) due to the molecular mechanisms involved in the loss of expression of PAX5 and that the identification of NOTCH1 could be considered as a candidate diagnostic/prognostic marker and a therapeutic target in pediatric cHL.